-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Climb Bio, Maintains $17 Price Target

Benzinga·06/12/2026 13:59:14
Listen to the news
Wedbush analyst Laura Chico reiterates Climb Bio (NASDAQ:CLYM) with a Outperform and maintains $17 price target.